Precision Prescribing in Psychiatry using Pharmcogenomics (Award Lecture-David Mrazek)-View Presentation

Video Transcription

Video Summary

The video features a lecture by Dr. Daniel Mueller, focused on pharmacogenetics in psychiatry, delivered as part of the Marazek Award presentation. Dr. Mueller, a senior scientist at the Center of Addiction and Mental Health and professor at the University of Toronto, explores the use of pharmacogenetics to enhance psychiatric treatment, specifically regarding antipsychotic-induced side effects like weight gain. The research identifies genetic markers related to these side effects, aiming for precision medicine to reduce the trial and error in drug prescriptions. Dr. Mueller's studies have highlighted substantial associations between these side effects and genes like the cannabinoid 1-receptor, melanocortin 4-receptor, dopamine D2 receptor, and neuropeptide Y.<br /><br />Mueller encourages integrating pharmacogenetic profiling into clinical practice. He emphasizes its role when confronted with treatment-resistant depression and underscores the economic benefits of implementing genetic testing before declaring an antidepressant regimen as unsuccessful. He references international consortiums and guidelines supporting pharmacogenetic applications, acknowledging its controversy and highlighting ongoing advancements. Throughout the narrative, he credits Dr. David Mrazek, a pioneer in the field, while also contextualizing the skepticism and challenges. Audience members inquire about insurance coverage, testing availability, and its validity across various medications, reflecting a robust interest in practical application and system integration. Dr. Mueller responds with evidence supporting the use of pharmacogenetic strategies, maintaining an informed and careful approach to this developing field in clinical settings.

Keywords

pharmacogenetics

psychiatry

Dr. Daniel Mueller

antipsychotic side effects

genetic markers

precision medicine

treatment-resistant depression

genetic testing

cannabinoid 1-receptor

melanocortin 4-receptor

dopamine D2 receptor

neuropeptide Y

clinical integration